Ciprofol vs Propofol for Reducing Hypoxia Incidence in ERCP

Anesthesia; Adverse Effect Clinical Trial

Official title:

Ciprofol vs Propofol for Reducing Hypoxia Incidence in Intravenous Anesthesia During Elective Endoscopic Retrograde Cholangiopancreatography-A Randomized Double Blinded Controlled Trial.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06015074
• Other study ID #: C-Anesthesia
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 15, 2024
• Est. completion date: February 28, 2025

Study information

• Verified date: May 2024
• Source: RenJi Hospital
• Contact: Peiying Li, Doctor
• Phone: 15800616866
• Email: peiyingli.md[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intravenous anesthesia has been widely used in endoscopic retrograde cholangiopancreatography (ERCP). In the past decade, many practices have been carried out under the propofol-based monitored anesthesia care without endotracheal intubation in patients undergoing ERCP.

Ciprofol is a newly developed intravenous anesthetic with a potency 4-5 times than that of propofol. Ciprofol seems a promising anesthetic agent for intravenous anesthesia but the evidence supported its application in ERCP is still limited.

Description:

This is a prospective, randomized, double-blind trial comparing the incidence of hypoxia in the propofol versus ciprofol intravenous Anesthesia. A total 136 patients will be recruited and randomly assigned to either the propofol or the ciprofol group. The primary outcome is the proportion of patients experiencing hypoxia. The secondary outcomes include: the incidence of hypotension in perioperative period; the incidence of conversion from intravenous anesthesia to general anesthesia; sedation-related procedure interruption; carbon dioxide( CO2) accumulation during operation; Patients' satisfaction with anesthesia and postoperative recovery / VAS score / incidence of nausea and vomiting; the incidence of intraoperative and postoperative adverse events, such as adverse excretion, severe hypoxemia, severe circulatory dysfunction; length of stay and mortality within 30 days after operation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 136
• Est. completion date: February 28, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients undergoing ERCP, ASA I-III

• normal renal function

• BMI = 18kg/m 2 and = 30kg/m 2

Exclusion Criteria:

• Previous serious cerebrovascular accidents and other neurological diseases

• mental diseases, long-term use of drugs that affect the function of the central nervous system, benzodiazepines or opioids

• history of anesthetic allergy

• preoperative hypotension or preoperative SpO2 < 90%, or chronic respiratory failure

• patients suspected of having difficult airways

• screening for drug addiction and alcohol abuse within the first 3 months (> = 6standarddrinks/day)

• patients diagnosed with severe cardiopulmonary disease, or respiratory or respiratory diseases such as sleep apnea syndrome;

• bradycardia or atrioventricular block.

• participate in other clinical trials within 4 weeks;

• cognitive or communication abnormalities determined by the researchers;

• emergent and critical conditions during the operation;

• other conditions that the researchers believe are not suitable to participate in the study.

Related Conditions & MeSH terms

• Anesthesia; Adverse Effect
• Biliary Tract Diseases
• Hypoxia

Intervention

Drug:
• Propofol
patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
• Ciprofol
patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.

Locations

Country	Name	City	State
China	Renji Hospital, Shanghai Jiao Tong University School of Medicine,	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

References & Publications (10)

Adler DG, Baron TH, Davila RE, Egan J, Hirota WK, Leighton JA, Qureshi W, Rajan E, Zuckerman MJ, Fanelli R, Wheeler-Harbaugh J, Faigel DO; Standards of Practice Committee of American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005 Jul;62(1):1-8. doi: 10.1016/j.gie.2005.04.015. No abstract available. — View Citation

Alzanbagi AB, Jilani TL, Qureshi LA, Ibrahim IM, Tashkandi AMS, Elshrief EEA, Khan MS, Abdelhalim MAH, Zahrani SA, Mohamed WMK, Nageeb AM, Abbushi B, Shariff MK. Randomized trial comparing general anesthesia with anesthesiologist-administered deep sedation for ERCP in average-risk patients. Gastrointest Endosc. 2022 Dec;96(6):983-990.e2. doi: 10.1016/j.gie.2022.06.003. Epub 2022 Jun 9. — View Citation

Amornyotin S, Srikureja W, Chalayonnavin W, Kongphlay S. Dose requirement and complications of diluted and undiluted propofol for deep sedation in endoscopic retrograde cholangiopancreatography. Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):313-8. doi: 10.1016/s1499-3872(11)60052-0. — View Citation

Cote GA, Hovis RM, Ansstas MA, Waldbaum L, Azar RR, Early DS, Edmundowicz SA, Mullady DK, Jonnalagadda SS. Incidence of sedation-related complications with propofol use during advanced endoscopic procedures. Clin Gastroenterol Hepatol. 2010 Feb;8(2):137-42. doi: 10.1016/j.cgh.2009.07.008. Epub 2009 Jul 14. — View Citation

Liu Y, Chen C, Liu N, Tong L, Nie Y, Wu J, Liu X, Gao W, Tang L, Guan X. Efficacy and Safety of Ciprofol Sedation in ICU Patients with Mechanical Ventilation: A Clinical Trial Study Protocol. Adv Ther. 2021 Oct;38(10):5412-5423. doi: 10.1007/s12325-021-01877-6. Epub 2021 Aug 21. — View Citation

Liu Y, Yu X, Zhu D, Zeng J, Lin Q, Zang B, Chen C, Liu N, Liu X, Gao W, Guan X. Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial. Chin Med J (Engl). 2022 May 5;135(9):1043-1051. doi: 10.1097/CM9.0000000000001912. — View Citation

Paspatis GA, Manolaraki MM, Vardas E, Theodoropoulou A, Chlouverakis G. Deep sedation for endoscopic retrograde cholangiopancreatography: intravenous propofol alone versus intravenous propofol with oral midazolam premedication. Endoscopy. 2008 Apr;40(4):308-13. doi: 10.1055/s-2007-995346. Epub 2007 Dec 5. — View Citation

Qadeer MA, Vargo JJ, Dumot JA, Lopez R, Trolli PA, Stevens T, Parsi MA, Sanaka MR, Zuccaro G. Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. Gastroenterology. 2009 May;136(5):1568-76; quiz 1819-20. doi: 10.1053/j.gastro.2009.02.004. — View Citation

Vargo JJ, Zuccaro G Jr, Dumot JA, Conwell DL, Morrow JB, Shay SS. Automated graphic assessment of respiratory activity is superior to pulse oximetry and visual assessment for the detection of early respiratory depression during therapeutic upper endoscopy. Gastrointest Endosc. 2002 Jun;55(7):826-31. doi: 10.1067/mge.2002.124208. — View Citation

Vargo JJ, Zuccaro G Jr, Dumot JA, Shermock KM, Morrow JB, Conwell DL, Trolli PA, Maurer WG. Gastroenterologist-administered propofol versus meperidine and midazolam for advanced upper endoscopy: a prospective, randomized trial. Gastroenterology. 2002 Jul;123(1):8-16. doi: 10.1053/gast.2002.34232. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the incidence of hypoxia	the definition of hypoxemia: any event of SpO2 (oxygen saturation measured by pulse oximetry) < 90%	from the induction of anesthesia to the patient leaving the postanesthesia care unit,about an average of 1.5 hours
Secondary	the incidence of hypercapnia	arterial carbon dioxide partial pressure(PaCO2)>50mmHg	5 minutes each time(base line, 10 minutes after beginning of surgery, completion of surgery, 10 minutes after awakening)
Secondary	the incidence of hypotension	invasive systolic pressure<90mmHg	from the induction of anesthesia to the patient leaving the postanesthesia care unit,about an average of 1.5 hours
Secondary	sedation-related procedure interruption	the incidence of interruption of procedure due to intolerance or severe adverse events	from the induction of anesthesia to completion of ERCP, about 30 minutes
Secondary	conversion from intravenous anesthesia to general anesthesia	the incidence of conversion from intravenous anesthesia to general anesthesia due to intolerance or severe adverse events	from the induction of anesthesia to completion of ERCP, about 30 minutes
Secondary	patient satisfaction score	Patients' satisfaction score is measured by patient recovery satisfaction score, from -33 the worst to 33 the best.	5 minutes
Secondary	visual analog scale (VAS) scores	perioperative pain is measured by visual analog scale (VAS) scores,from painless score 0 to the imagined most severe pain score 10	30 seconds
Secondary	length of stay	length of stay in hospital	2-7days
Secondary	the incidence of postoperative adverse bile excretion	patients with symptoms or signs of postoperative adverse bile excretion	30 days after operation
Secondary	the incidence of severe postoperative hypoxia	patients with symptoms or signs of severe postoperative hypoxia	30 days after operation
Secondary	the incidence of severe postoperative circulatory disfunction	patients with symptoms or signs of severe postoperative circulatory disfunction	30 days after operation
Secondary	the incidence of mortality within 30 days after operation	mortality within 30 days after operation	30 days after operation